Photo from Mohamed Benlazar/X
Dec 11, 2024, 11:32
Mohamed Benlazar: Ziftomenib with venetoclax/azacitidine in R/R AML with NPM1 mutations or KMT2A rearrangements
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on X:
“Ziftomenib combined with venetoclax/azacitidine in patients with R/R AML with NPM1 mutations or KMT2A rearrangements.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 31, 2025, 20:25
Mar 31, 2025, 20:00
Mar 31, 2025, 19:01
Mar 31, 2025, 18:51
Mar 31, 2025, 18:40
Mar 31, 2025, 18:40